Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that
affects patients' function, quality of life, and ability to tolerate treatment. In certain patients …

The scope of dermatologic adverse events to ibrutinib has not been systematically
described. We sought to determine the incidence and severity of ibrutinib-associated …

Background Advances in molecular biology and genetics have contributed to breakthrough
treatments directed at specific pathways associated with the development of cancer. Small …

B‐cell chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the United
States, and its diagnosis can have many dermatologic implications. For one, the cutaneous …

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has revolutionised the treatment for
multiple lymphoproliferative disorders and chronic graft versus host disease [1]. It is explored …

Ibrutinib is a Bruton tyrosine kinase inhibitor used to treat many hematologic conditions,
most commonly B‐cell lymphomas and leukemias. Reportedly, skin rash is an adverse event …

Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B-cell lymphoproliferative
disorders. Patients with genetic BTK deficiency are susceptible to recurrent and severe …

A limited literature search was conducted by an information specialist on key resources,
including MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the …

Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib
Page 1 CPD • A memorable patient CED Clinical and Experimental Dermatology CPD …